NAD+: Molecular Structure

Molecular Structure and Properties#

NAD+ is a dinucleotide whose molecular structure and properties have been characterized extensively through X-ray crystallography, NMR spectroscopy, and computational chemistry.

Chemical Structure#

NAD+ (nicotinamide adenine dinucleotide, C21H27N7O14P2, MW 663.43 Da) is composed of two nucleotides joined by a pyrophosphate bridge. One nucleotide contains an adenine base, the other a nicotinamide base. Each base is attached to a ribose sugar, and the two ribose sugars are linked through their 5' positions by a pyrophosphate group.

Structural components:

• Nicotinamide moiety: The pyridine ring of nicotinamide is the functional site for hydride transfer. In the oxidized form (NAD+), the nitrogen of the nicotinamide ring carries a positive charge. During reduction, the C4 position of the nicotinamide ring accepts a hydride ion (H-), forming NADH and losing the positive charge.
• Adenine moiety: The adenine base participates in enzyme recognition and binding but does not directly participate in the redox chemistry.
• Pyrophosphate bridge: Links the two nucleotides and contributes to the overall negative charge of the molecule at physiological pH.
• Ribose sugars: D-ribofuranose in both nucleotides; the adenine ribose bears a 2'-hydroxyl group that distinguishes NAD+ from NADP+ (which has a 2'-phosphate).

Redox Chemistry#

NAD+/NADH interconversion

• The nicotinamide ring of NAD+ accepts two electrons and one proton (a hydride equivalent) at the C4 position, converting to NADH. This reaction is stereospecific: enzymes transfer hydride to either the A-face (pro-R) or B-face (pro-S) of the nicotinamide ring.
• The redox potential of the NAD+/NADH couple is approximately -320 mV at pH 7.0, making it thermodynamically favorable for oxidizing a wide range of metabolic substrates.
• NADH absorbs UV light at 340 nm (extinction coefficient approximately 6,220 M-1 cm-1), while NAD+ does not, enabling spectrophotometric assay of NAD+/NADH-dependent reactions.

NAD+ vs NADP+ distinction

• NADP+ differs from NAD+ by a single phosphate group at the 2'-hydroxyl of the adenine ribose. Despite this small structural difference, cellular metabolism maintains distinct NAD+/NADH and NADP+/NADPH pools with different redox ratios and different metabolic roles: NAD+/NADH primarily participates in catabolic (energy-generating) reactions, while NADP+/NADPH supports anabolic (biosynthetic) and antioxidant functions.

Biosynthesis Pathways#

NAD+ is synthesized through three converging pathways:

De novo pathway (from tryptophan)

• Tryptophan is converted to N-formylkynurenine by indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO), then through several enzymatic steps to quinolinic acid, which is converted to nicotinic acid mononucleotide (NaMN) by quinolinic acid phosphoribosyltransferase (QPRT). NaMN is then adenylated by NMNATs to NaAD+, and finally amidated by NAD+ synthetase (NADS) to NAD+.
• This pathway contributes minimally to NAD+ pools in most tissues but is significant in the liver and immune cells (where IDO is upregulated by inflammatory stimuli such as interferon-gamma).

Preiss-Handler pathway (from nicotinic acid)

• Nicotinic acid (niacin, vitamin B3) is converted to NaMN by nicotinic acid phosphoribosyltransferase (NAPRT), then to NaAD+ by NMNATs, and finally to NAD+ by NAD+ synthetase.
• This pathway can be significant when dietary niacin intake is high or when nicotinic acid is administered therapeutically.

Salvage pathway (from nicotinamide)

• Nicotinamide (NAM), the byproduct released by sirtuins, PARPs, and CD38 when they consume NAD+, is recycled back to NMN by nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of NAD+ salvage.
• NMN is converted to NAD+ by NMN adenylyltransferases (NMNAT1 in the nucleus, NMNAT2 in the cytoplasm/Golgi, NMNAT3 in mitochondria).
• NAMPT expression and activity decline with age in multiple tissues, contributing to age-related NAD+ depletion.
• Nicotinamide riboside (NR) enters the salvage pathway through phosphorylation by NR kinases (NRK1/NRK2) to produce NMN.

Compartmentalization#

NAD+ is distributed across distinct subcellular compartments, each with its own pool and regulatory mechanisms:

• Nuclear NAD+: Supports PARP-mediated DNA repair and sirtuin-dependent histone deacetylation/gene regulation. NMNAT1 synthesizes NAD+ locally.
• Cytoplasmic NAD+: Supports glycolysis and cytoplasmic sirtuin (SIRT2) activity. NMNAT2 is the cytoplasmic synthase and is essential for neuronal viability.
• Mitochondrial NAD+: Supports the TCA cycle, electron transport chain, and mitochondrial sirtuins (SIRT3-5). The mitochondrial NAD+ pool is thought to be maintained semi-independently, with some evidence for NAD+ transport across the inner mitochondrial membrane.
• NAD+ does not freely cross lipid bilayers; transport between compartments involves specific transporters (e.g., Slc25a51 for mitochondrial NAD+ import) and local synthesis by compartment-specific NMNATs.

Stability and Formulation#

pH stability

• NAD+ is most stable in slightly acidic to neutral conditions (pH 4-7). Under strongly acidic conditions (pH <2), the nicotinamide-ribose glycosidic bond is cleaved. Under alkaline conditions (pH >8), the pyridinium ring of NAD+ is susceptible to ring-opening and epimerization, reducing biological activity.
• NADH is less stable than NAD+ in solution, particularly under acidic conditions where it degrades more rapidly.

Temperature sensitivity

• NAD+ in aqueous solution is stable for hours at room temperature (20-25 C) and for days at 4 C when buffered near neutral pH.
• Lyophilized NAD+ is stable for months to years when stored at -20 C in sealed containers protected from moisture and light.
• Repeated freeze-thaw cycles should be minimized for NAD+ solutions, as each cycle accelerates degradation.

Degradation pathways

• Enzymatic degradation: CD38, PARPs, and sirtuins consume NAD+ in biological systems. CD38 is the dominant NADase and a primary driver of NAD+ degradation in tissues.
• Non-enzymatic degradation: Hydrolysis of the glycosidic bond (especially at elevated temperature or extreme pH) and oxidation of NADH to NAD+ (and further degradation products) are the primary non-enzymatic routes.
• Light sensitivity: NAD+ and especially NADH are sensitive to UV light; solutions should be protected from light exposure during storage and handling.

Formulation considerations

• IV formulations: Typically prepared as sterile solutions in normal saline at concentrations of 100-200 mg/mL, pH adjusted to 5.0-7.0, and administered fresh or within hours of preparation.
• Lyophilized powder: Preferred for long-term storage; reconstituted immediately before use with sterile water or buffered saline.
• Oral precursors: NR and NMN have superior oral bioavailability compared to NAD+ itself, which is rapidly degraded in the GI tract.

Pharmacokinetics#

Absorption

• Intravenous: Direct systemic delivery; plasma NAD+ rises rapidly during infusion. In clinical settings, IV NAD+ is typically infused over 2-8 hours at doses of 250-1000 mg per session.
• Oral NAD+: Very poor bioavailability due to extensive degradation by intestinal and hepatic enzymes; intact NAD+ absorption is negligible. Oral precursors (NR, NMN) are the preferred oral route.
• Oral NR: Absorbed intact via nucleoside transporters; converted to NAM in the liver and other tissues, then to NMN and NAD+ via the salvage pathway. Demonstrated to raise blood NAD+ by 40-90% at 1000 mg/day in human trials.
• Oral NMN: Absorbed via Slc12a8 and potentially via dephosphorylation to NR followed by re-phosphorylation; demonstrated to raise blood NAD+ in human trials.
• Intranasal: Under investigation; limited pharmacokinetic data in humans.

Distribution

• NAD+ is present in all cell types. Intracellular concentrations range from approximately 0.2-0.5 mM, with the highest concentrations in metabolically active tissues (liver, kidney, heart, brain).
• Plasma NAD+ levels are much lower (approximately 20-50 nM in healthy adults) and decline with age.

Metabolism and elimination

• Exogenous NAD+ is rapidly metabolized in circulation by CD38 and other ecto-NADases to nicotinamide (NAM) and ADP-ribose metabolites.
• NAM is the primary circulating metabolite and is either recycled through the salvage pathway or methylated to N1-methylnicotinamide (MeNAM) for renal excretion.
• The effective circulating half-life of IV NAD+ is short (estimated 30-45 minutes), but cellular NAD+ pools turn over more slowly (1-6 hours depending on tissue and metabolic conditions).

Related Reading#

• NAD+ overview and research guide
• Peptides similar to NAD+
• NAD+ research evidence